Demonstrated immune response following a single intramuscular injection
Rates of ≥4-fold increase in serogroup SBA* titers after administration of Menactra vaccine (n=425) or the meningococcal polysaccharide vaccine (n=423).1
- Menactra vaccine produces antibody responses to serogroups A, C. Y, and W-135 that are equivalent to the meningococcal polysaccharide vaccine1
- 82% to 97% of adolescents achieved a ≥4-fold rise in antibody titers for serogroups A, C, Y, and W-135 following administration of Menactra vaccine1
- Among seronegative adolescents, 98% to 100% achieved a ≥4-fold rise in antibody titers for serogroups A, C, Y, and W-135 following administration of Menactra vaccine (n=425)1
- Three years after initial vaccination, Menactra vaccine produced a strong booster response in previously vaccinated adolescents (n=76)1
Reference:
1. Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005;159:907-913.